Watch KALA. Know when insiders buy.
One email the day a filing lands. Free.
KALA
KALA BIO, Inc.
0.54
−0.03 −4.60%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $10.4MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$10.1MNET DEBT $26.7M52W 0.51 – 956.75SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$1.7M | −$1.6M | — | -21.32 | −$1.5M | — | — | Aug 19 |
| Q1 2026 · Mar 31 | — | — | — | −$1.8M | −$1.6M | — | -0.14 | −$2.9M | — | — | May 15 |
| Q4 2025 · Dec 31derived | — | — | — | −$10.2M | $686K | — | 0.86 | −$4.6M | — | — | Apr 15 |
| Q3 2025 · Sep 30 | — | — | — | −$7.2M | −$7.6M | — | -1.07 | −$10.9M | — | — | Nov 19 |
| Q2 2025 · Jun 30 | — | — | — | −$11M | −$11.2M | — | -85.64 | −$16.6M | — | — | Aug 19 |
| Q1 2025 · Mar 31 | — | — | — | −$10.7M | −$8.9M | — | -70.49 | −$8.8M | — | — | May 15 |
| Q4 2024 · Dec 31derived | — | — | — | −$9.5M | −$8.2M | — | -1.47 | −$4.6M | — | — | Apr 15 |
| Q3 2024 · Sep 30 | — | — | — | −$10M | −$8.9M | — | -1.93 | −$4.7M | — | — | Nov 19 |
| Q2 2024 · Jun 30 | — | — | — | −$9.6M | −$9.6M | — | -3.16 | −$9.2M | — | — | Aug 8 |
| Q1 2024 · Mar 31 | — | — | — | −$11.9M | −$11.8M | — | -4.20 | −$10.8M | — | — | May 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$9.6M | −$8.6M | — | -2.99 | −$7.7M | — | — | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$8.8M | −$8.7M | — | -3.41 | −$3M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$39.2M | −$27M | — | -3.31 | −$32M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$41M | −$38.5M | — | -10.15 | −$29.4M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$39.7M | −$42.2M | — | -17.35 | −$27.9M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$81.7M | −$44.8M | — | -29.48 | −$78.9M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$130.2M | −$142.6M | — | -108.32 | −$108.2M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$96.2M | −$104.3M | — | -1.99 | −$90.7M | — | — | — | — |
Every number comes from KALA BIO, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.